Trial Profile
A Phase 3b Randomized, Open-Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI + RTV) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically-Suppressed, HIV-1 Infected Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Peptide hydrolase inhibitors; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms STRATEGY-PI
- Sponsors Gilead Sciences
- 19 Aug 2015 Results published in The Patient - Patient-Centered Outcomes Research.
- 22 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Apr 2014 Planned end date changed from 1 Dec 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.